The value of prognostic and treatment response evaluation of 18F-FDG PET/CT in lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200065580

Enrollment

Unknown

Registered

2022-11-09

Start date

2022-11-28

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma

Interventions

Observational study:None

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. pathologically confirmed lymphoma; 2. without any treatment; 3. complete medical and follow-up data; 4. without previous history of cancer; 5. baseline 18F-FDG PET/CT.

Exclusion criteria

Exclusion criteria: 1. previous history of cancer; 2. any treatment before 18F-FDG PET/CT; 3. lost to follow-up; 4. incomplete medical data; 5. Contraindications of PET/CT examination, such as hyperglycemia.

Design outcomes

Primary

Measure	Time frame
SUVmax;MTV;TLG;progression free survival;overall survival;complete?response;partial?response;stable disease;progression disease;	—

Countries

China

Contacts

Public ContactChong Jiang

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

jiangc_nju@163.com+86 18795840983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026